FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4312113878> ?p ?o ?g. }

• W4312113878 endingPage "635" @default.
• W4312113878 startingPage "626" @default.
• W4312113878 abstract "The human epidermal growth factor receptor 2 (HER2) is an established therapeutic target for various kinds of solid tumors. HER2 amplification occurs in approximately 1% to 6% of colorectal cancer. In this study, we aimed to assess the efficacy and safety of trastuzumab in combination with chemotherapy in HER2-positive metastatic colorectal cancer (mCRC).An open-label, phase II trial (Clinicaltrials.gov: NCT03185988) was designed to evaluate the antitumor activity of trastuzumab and chemotherapy in HER2-positive digestive cancers excluding gastric cancer in 2017. Patients from this trial with HER2-positive, KRAS/BRAF wild-type, unresectable mCRC were analyzed in this manuscript. Eligible patients were treated with trastuzumab (8 mg/kg loading dose and then 6 mg/kg every 3 weeks) and irinotecan (120 mg/m2 days 1 and 8 every 3 weeks). The primary endpoint was the objective response rate.Twenty-one HER2-positive mCRC patients were enrolled in this study. Seven patients (33.3%) achieved an objective res-ponse, and 11 patients (52.4%) had stable disease as their best response. The median progression-free survival (PFS) was 4.3 months (95% confidence interval, 2.7 to 5.9). Four of the 21 patients (19.0%) had grade 3 adverse events, including leukopenia, neutropenia, urinary tract infection, and diarrhea. No treatment-related death was reported. Exploratory analyses revealed that high tumor tissue HER2 copy number was associated with better therapeutic response and PFS. Alterations in the mitogen-activated protein kinase pathway, HER2 gene, phosphoinositide 3-kinase/AKT pathway, and cell cycle control genes were potential drivers of trastuzumab resistance in mCRC.Trastuzumab combined with chemotherapy is a potentially effective and well-tolerated therapeutic regimen in mCRC with a high HER2 copy number." @default.
• W4312113878 created "2023-01-04" @default.
• W4312113878 creator A5003866201 @default.
• W4312113878 creator A5004181171 @default.
• W4312113878 creator A5004648803 @default.
• W4312113878 creator A5006511913 @default.
• W4312113878 creator A5023399359 @default.
• W4312113878 creator A5035655693 @default.
• W4312113878 creator A5035716717 @default.
• W4312113878 creator A5046118596 @default.
• W4312113878 creator A5052883326 @default.
• W4312113878 creator A5065225564 @default.
• W4312113878 creator A5065755796 @default.
• W4312113878 creator A5072537482 @default.
• W4312113878 creator A5076447792 @default.
• W4312113878 creator A5080326933 @default.
• W4312113878 date "2023-04-15" @default.
• W4312113878 modified "2023-10-17" @default.
• W4312113878 title "Trastuzumab combined with irinotecan in patients with HER2-positive metastatic colorectal cancer: A phase II single-arm study and exploratory biomarker analysis" @default.
• W4312113878 cites W1966937303 @default.
• W4312113878 cites W1968881689 @default.
• W4312113878 cites W1991071047 @default.
• W4312113878 cites W2034338421 @default.
• W4312113878 cites W2038081635 @default.
• W4312113878 cites W2100439220 @default.
• W4312113878 cites W2104580737 @default.
• W4312113878 cites W2107831804 @default.
• W4312113878 cites W2113868669 @default.
• W4312113878 cites W2134748703 @default.
• W4312113878 cites W2147674085 @default.
• W4312113878 cites W2147834058 @default.
• W4312113878 cites W2262414037 @default.
• W4312113878 cites W2336815607 @default.
• W4312113878 cites W2342934617 @default.
• W4312113878 cites W2507354993 @default.
• W4312113878 cites W2783112448 @default.
• W4312113878 cites W2792494514 @default.
• W4312113878 cites W2796050424 @default.
• W4312113878 cites W2810059108 @default.
• W4312113878 cites W2810647922 @default.
• W4312113878 cites W2828180271 @default.
• W4312113878 cites W2893194336 @default.
• W4312113878 cites W2921113926 @default.
• W4312113878 cites W2921243012 @default.
• W4312113878 cites W2968648521 @default.
• W4312113878 cites W2976352116 @default.
• W4312113878 cites W3021411361 @default.
• W4312113878 doi "https://doi.org/10.4143/crt.2022.1058" @default.
• W4312113878 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36550683" @default.
• W4312113878 hasPublicationYear "2023" @default.
• W4312113878 type Work @default.
• W4312113878 citedByCount "3" @default.
• W4312113878 countsByYear W43121138782023 @default.
• W4312113878 crossrefType "journal-article" @default.
• W4312113878 hasAuthorship W4312113878A5003866201 @default.
• W4312113878 hasAuthorship W4312113878A5004181171 @default.
• W4312113878 hasAuthorship W4312113878A5004648803 @default.
• W4312113878 hasAuthorship W4312113878A5006511913 @default.
• W4312113878 hasAuthorship W4312113878A5023399359 @default.
• W4312113878 hasAuthorship W4312113878A5035655693 @default.
• W4312113878 hasAuthorship W4312113878A5035716717 @default.
• W4312113878 hasAuthorship W4312113878A5046118596 @default.
• W4312113878 hasAuthorship W4312113878A5052883326 @default.
• W4312113878 hasAuthorship W4312113878A5065225564 @default.
• W4312113878 hasAuthorship W4312113878A5065755796 @default.
• W4312113878 hasAuthorship W4312113878A5072537482 @default.
• W4312113878 hasAuthorship W4312113878A5076447792 @default.
• W4312113878 hasAuthorship W4312113878A5080326933 @default.
• W4312113878 hasBestOaLocation W43121138781 @default.
• W4312113878 hasConcept C121608353 @default.
• W4312113878 hasConcept C126322002 @default.
• W4312113878 hasConcept C143998085 @default.
• W4312113878 hasConcept C203092338 @default.
• W4312113878 hasConcept C2776694085 @default.
• W4312113878 hasConcept C2777063308 @default.
• W4312113878 hasConcept C2779786085 @default.
• W4312113878 hasConcept C2779984678 @default.
• W4312113878 hasConcept C2780259306 @default.
• W4312113878 hasConcept C2780873365 @default.
• W4312113878 hasConcept C2781187634 @default.
• W4312113878 hasConcept C31760486 @default.
• W4312113878 hasConcept C526805850 @default.
• W4312113878 hasConcept C530470458 @default.
• W4312113878 hasConcept C535046627 @default.
• W4312113878 hasConcept C71924100 @default.
• W4312113878 hasConcept C90924648 @default.
• W4312113878 hasConceptScore W4312113878C121608353 @default.
• W4312113878 hasConceptScore W4312113878C126322002 @default.
• W4312113878 hasConceptScore W4312113878C143998085 @default.
• W4312113878 hasConceptScore W4312113878C203092338 @default.
• W4312113878 hasConceptScore W4312113878C2776694085 @default.
• W4312113878 hasConceptScore W4312113878C2777063308 @default.
• W4312113878 hasConceptScore W4312113878C2779786085 @default.
• W4312113878 hasConceptScore W4312113878C2779984678 @default.
• W4312113878 hasConceptScore W4312113878C2780259306 @default.
• W4312113878 hasConceptScore W4312113878C2780873365 @default.
• W4312113878 hasConceptScore W4312113878C2781187634 @default.
• W4312113878 hasConceptScore W4312113878C31760486 @default.

• next